1117-AB81 202304 Unified Agenda of Federal Regulatory and Deregulatory Actions 1117 Drug Enforcement Administration DEA 1100 Department of Justice DOJ Implementation of the Designer Anabolic Steroid Control Act of 2014

On December 18, 2014, the Designer Anabolic Steroid Control Act of 2014 (DASCA) became law.  The Act amended the Controlled Substances Act to revise and add specified substances to the definition of anabolic steroid.  The Act provided a new mechanism for temporary and permanent scheduling of anabolic steroids, and added specific labeling requirements for products containing anabolic steroids.  The Drug Enforcement Administration (DEA) is publishing this rule to amend and reorganize its regulations to make them consistent with DASCA regarding the updated definition, specific substances, criteria and timeframes applicable to temporary and permanent scheduling of anabolic steroids, and labeling requirements.

]]> Substantive, Nonsignificant Previously Published in The Unified Agenda Final Rule Stage Undetermined No 21 CFR 1300 21 CFR 1302 21 CFR 1308 21 U.S.C. 802 21 U.S.C. 811 21 U.S.C. 812 21 U.S.C. 821 21 U.S.C. 825 21 U.S.C. 842 21 U.S.C. 871(b) 21 U.S.C. 951 21 U.S.C. 956(b) 21 U.S.C. 958(e) No Final Action 07/00/2023 DEA Docket number 481 No No None No DPE@dea.gov www.regulations.gov No No Scott Brinks A. Section Chief, Regulatory Drafting and Support Section, Diversion Control Division 1117 Drug Enforcement Administration DEA 571 362-8209 scott.a.brinks@dea.gov 8701 Morrissette Drive, Springfield VA 22152